Ankur Drugs & Pharma Ltd. - Research Center
531683 ANKURDRUGS Group (T) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 12 | Mar ' 11 | Mar ' 10 | Mar ' 09 | Mar ' 08 | |
|---|---|---|---|---|---|
| Sales | 153.08 | 824.00 | 1,067.53 | 965.32 | 673.65 |
| Operating profit | -28.11 | 123.82 | 213.21 | 132.17 | 105.77 |
| Interest | 72.86 | 108.22 | 65.97 | 54.10 | 24.45 |
| Gross profit | -100.90 | 16.41 | 148.87 | 81.00 | 81.84 |
| EPS (Rs) | -114.56 | -33.67 | 46.24 | 19.94 | 50.96 |
Annual
results in details
| Mar ' 12 | Mar ' 11 | Mar ' 10 | Mar ' 09 | Mar ' 08 | |
|---|---|---|---|---|---|
| Other income | 0.07 | 0.81 | 1.63 | 2.94 | 0.52 |
| Stock adjustment | 18.68 | 39.62 | -3.72 | -46.34 | -4.17 |
| Raw material | 93.58 | 571.75 | 799.38 | 784.42 | 535.70 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 28.91 | 29.73 | 20.24 | 18.44 | 10.79 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | 55.69 | 25.56 |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 40.01 | 48.63 | 38.42 | - | - |
| Provisions made | - | 10.45 | - | 20.94 | - |
| Depreciation | 66.03 | 60.81 | 26.78 | 20.67 | 5.22 |
| Taxation | 31.27 | 20.94 | 34.00 | 21.80 | 11.90 |
| Net profit / loss | -221.57 | -65.13 | 89.44 | 37.13 | 64.73 |
| Extra ordinary item | -23.37 | 0.21 | 1.34 | -1.42 | - |
| Prior year adjustments | - | - | - | 0.01 | - |
| Equity capital | 19.34 | 19.34 | 19.34 | 18.62 | 12.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | 161.21 | 146.02 | 122.21 | 119.00 | 91.70 |
| Agg.of non promotoholding (%) | 83.35 | 75.49 | 63.19 | 63.92 | 72.20 |
| OPM (%) | -18.36 | 15.03 | 19.97 | 13.69 | 15.70 |
| GPM (%) | -65.89 | 1.99 | 13.92 | 8.37 | 12.14 |
| NPM (%) | -144.68 | -7.90 | 8.36 | 3.83 | 9.60 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis